Showing 4,321 - 4,340 results of 101,525 for search '(( 50 ((nn decrease) OR (mean decrease)) ) OR ( 5 ((ng decrease) OR (a decrease)) ))', query time: 0.92s Refine Results
  1. 4321
  2. 4322
  3. 4323
  4. 4324
  5. 4325

    Image4_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  6. 4326

    Image2_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  7. 4327

    Image6_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  8. 4328

    Image1_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  9. 4329

    Image3_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  10. 4330

    Image7_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  11. 4331

    Table1_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.xlsx by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  12. 4332

    Carbon−Sulfur Bond Formation via Alkene Addition to an Oxidized Ruthenium Thiolate by Craig A. Grapperhaus (1666657)

    Published 2007
    “…During oxidation, the absorption bands of <b>1b</b> at 540, 797, and 1041 nm decrease in intensity. The resulting complex <b>[2a]</b><b><sup>+</sup></b><sup></sup> displays a single redox couple at +804 mV. …”
  13. 4333
  14. 4334

    The thromboxane analogue, U-46619 decreased vessel diameter. by Simon C. Watkins (39900)

    Published 2012
    “…Changes in aortic flow velocity (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0044018#pone-0044018-g005" target="_blank">Figure 5</a>) in response to U-46619 in the 5 dpf embryos, were accompanied by decreases in vessel diameter (<b>E</b>, n = 5, <i>P</i><0.05). χ denotes statistical differences from baseline (time 0).…”
  15. 4335

    High glucose decreases antioxidant activities in endothelial cells. by Zhaoyun Zhang (118032)

    Published 2012
    “…Measurements were performed as described in Methods. High glucose causes a decrease in multiple antioxidant enzymes. A: G6PD activity. …”
  16. 4336
  17. 4337
  18. 4338
  19. 4339

    Rapamycin acts in the brain to decrease body weight gain. by Mark Hebert (558822)

    Published 2014
    “…<p>A and B: RAP i.c.v. injection (Day 0, broken line) induces a transient decrease in body weight gain (A), which results in prolonged shift in body weight (B). …”
  20. 4340